89Zr-DFO-naxitamab

N/A

Report date: 2025/12/05 11:43:40

Base Information

Drug Name89Zr-DFO-naxitamab

Drug Alias Name89Zr-DFO-naxitamab

ClassificationRadiation-emitting products > Nuclides > Zirconium > 89ZrRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionDisialoganglioside GD2 binders

TargetsDisialoganglioside GD2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesY-Mabs Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesY-Mabs Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A